VivoSeq
Gastroenterology

Cholangitis

11

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Cholangitis is an emerging landscape with 11 programs across 4 companies. The most active players are GSK, Fresenius Kabi Oncology Ltd., Intercept Pharmaceuticals. 8 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

ApprovedI

Intercept Pharmaceuticals

1 program

ApprovedSanofi logo

Sanofi

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Recruiting3 · 38%
Completed2 · 25%
Unknown status2 · 25%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
Recruiting·—·N/A·NCT05925309·356 enrolled
Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis
Recruiting·NNational University of Malaysia·Phase 2·NCT07407491·172 enrolled
Development and Internal Validation of a Multidimensional Composite Index for Outcome Burden in Acute Cholangitis: A Multicentre Retrospective Cohort Study in India
Recruiting·AAsian Institute of Gastroenterology, India·N/A·NCT07667166·514 enrolled
Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis
Active, not recruiting·—·N/A·NCT05750966·440 enrolled
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy
Completed·TTongji Hospital·Phase 4·NCT04370145·160 enrolled
Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting
Completed·TTehran University of Medical Sciences·N/A·NCT01148693·114 enrolled
Ketofol Versus Propofol in Urgent ERCP for Acute Cholangitis
Unknown status·—·Phase 4·NCT04997967·100 enrolled
Antibiotics to Decrease Post ERCP Cholangitis
Unknown status·UUniversity of Southern California·Phase 4·NCT03087656·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)